

10545005659 0584

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 513 653 163 US, in an envelope addressed to: MS PCT/DO/EU/OS, Commissioner for Patents, P.O. Box m50, Alexandria, VA 22313-1450 on the date shown below.

Dated: January 24, 2006 Signature:

Lilla Olsson

Patent
Docket No. 500862003600

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re Patent Application of:
Dominique P. BRIDON et al.**

Serial No.: Not Yet Assigned

Filing Date: Concurrently Herewith

For: LONG LASTING INSULIN
DERIVATIVES AND METHODS
THEREOF

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS PCT/DO/EO/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.**

Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

Application No. Not Yet Assigned
Information Disclosure Statement

2

Docket No. 500862003600

- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of __ is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Application No. Not Yet Assigned

3

Docket No. 500862003600

Information Disclosure Statement

~~AP200862003600~~ 01/24/2006

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 500862003600.

Dated: January 24, 2006

Respectfully submitted,

By Michael R. Ward

Michael R. Ward

Registration No.: 38,651
MORRISON & FOERSTER LLP
425 Market Street
San Francisco, California 94105-2482
(415) 268-6237

IAP20 RECEIVED 24 JAN 2006

ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO				Complete If Known	
				Not Yet Assigned	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Concurrently Herewith	
(Use as many sheets as necessary)				First Named Inventor Dominique P. BRIDON	
Sheet	1	of	1	Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	500862003600

U.S. PATENT DOCUMENTS					
Examiner Initials* /CB/	Cite No. ¹	Document Number Number+Kind Code* (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/CB/	1.	US-3,868,356	02-25-1975	Smyth	
/CB/	2.	US-3,868,357	02-25-1975	Smyth et al.	
/CB/	3.	US-6,323,311-B1	11-27-2001	Liu et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials* /CB/	Cite No. ¹	Foreign Patent Document Country Code*+Number+Kind Code* (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/CB/	4.	CA-2334859	12-23-1999	Kings College London	T ¹
/CB/	5.	CA-2363712	11-23-2000	ConjuChem	
/CB/	6.	WO-95/05187	02-23-1995	United Medical & Dental Schools of Guys and St. Thomas' Hospitals	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/CB/	7.	International Search Report issued December 21, 2004, for international patent application PCT/CA2004/001409, filed July 26, 2004, 5 pages			
/CB/	8.	BAUDYS et al. (1998) "Extending insulin action in vivo by conjugation to carboxymethyl dextran," Bioconjugate Chemistry, 9: 176-183			
/CB/	9.	JONASSEN et al. (Nov. 30, 1997) "Fatty acid acylated insulins display protracted action due to binding to serum albumin," In: Peptide Science: Present and Future, Proceedings of the International Peptide Symposium, Kyoto, pages 647-677			
/CB/	10.	THIBAUDEAU et al. (June 4-8, 2004) "Development of novel DAC insulin analogues with extended pharmacodynamic profiles," American Diabetes Association 64th Scientific Sessions, Orlando, Florida, Abstract 488-P			
/CB/	11.	UCHIO et al. (1999) "Site specific insulin conjugates with enhanced stability and extended action profile," Advanced Drug Delivery Reviews 35, 35(2,3): 289-306			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Christina Bradley/ (10/06/2008)	Date Considered
sf-2023825		